Zhejiang Jianfeng Group (600668.SH) announced that recently, the company's wholly-owned subsidiary Zhejiang Jianfeng Pharmaceutical Co., Ltd. (referred to as...
According to Zhitong Finance APP, Zhejiang Jianfeng Group (600668.SH) announced that recently, its wholly-owned subsidiary Zhejiang Jianfeng Pharmaceutical Co., Ltd. (referred to as 'Jianfeng Pharmaceutical') has received the glass sodium hyaluronate eye drops [Specification: 0.3% (0.4ml: 1.2mg)] 'Drug Registration Certificate' approved and issued by the National Medical Products Administration.
The approved 0.3% (0.4ml: 1.2mg) specification of glass sodium hyaluronate eye drops is suitable for epithelial damage of the cornea and conjunctiva associated with the following diseases: Sjögren's syndrome, Stevens-Johnson syndrome, and dry eye syndrome among other endogenous diseases; as well as exogenous diseases such as postoperative, drug-induced, trauma, and contact lens wear.